Neuren Pharmaceuticals Share Price and Company Fundamentals
Last traded: Today at 5:55 AM
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, and Pitt Hopkins syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 2001 and is based in Camberwell, Australia.
|Primary activities||Biopharmaceutical company with a focus on neurological conditions.|
|Industry / Sector||Biotechnology / Healthcare|
|Mailing address||697 Burke Road Suite 201 Camberwell VIC 3124 Australia|
|Phone / Fax||61 3 9092 0480 /|
|Share registry||LINK MARKET SERVICES LIMITED|
Neuren Pharmaceuticals does not pay dividends.
As of May 2021, following are the company executives and directors listed on Neuren Pharmaceuticals.
|Mr. Jonathan Charles Pilcher A.C.A., B.Sc., BSc (Hons), ACA||Chief Exec. Officer|
|Ms. Lauren Frazer C.A.||CFO & Company Sec.|
|Mr. Lawrence Glass||Chief Science Officer|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Neuren Pharmaceuticals is 149.95M and its enterprise value is 123.08M. The enterprise value to revenue ratio of NEU is 150.65.
The NEU's stocks Beta value is 1.43 making it 43% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Neuren Pharmaceuticals (NEU)
Neuren Pharmaceuticals (ASX:NEU) Frequently Asked Questions
1. What is Neuren Pharmaceuticals's Stock Symbol?
Neuren Pharmaceuticals trades on ASX under the ticker symbol "NEU".
2. What is Neuren Pharmaceuticals's stock price today?
One share of NEU stock can currently be purchased for approximately $1.275.
3. How can I contact Neuren Pharmaceuticals?
Neuren Pharmaceuticals's mailing address is 697 Burke Road Suite 201 Camberwell VIC 3124 Australia. The company can be reached via phone at 61 3 9092 0480.
4. What is Neuren Pharmaceuticals's official website?
The official website of Neuren Pharmaceuticals is http://www.neurenpharma.com.
5. Which share registry manages Neuren Pharmaceuticals's stock?
Neuren Pharmaceuticals's stock is managed by LINK MARKET SERVICES LIMITED.